Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis
Aliza P. Wingo, Yue Liu, Ekaterina S. Gerasimov, et al.
Nature Genetics (2021) Vol. 53, Iss. 2, pp. 143-146
Open Access | Times Cited: 290

Showing 1-25 of 290 citing articles:

New insights into the genetic etiology of Alzheimer’s disease and related dementias
Céline Bellenguez, Fahri Küçükali, Iris E. Jansen, et al.
Nature Genetics (2022) Vol. 54, Iss. 4, pp. 412-436
Open Access | Times Cited: 1508
Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level
Erik C. B. Johnson, Kathleen Carter, Eric B. Dammer, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 2, pp. 213-225
Open Access | Times Cited: 377
Stroke genetics informs drug discovery and risk prediction across ancestries
Aniket Mishra, Rainer Malik, Tsuyoshi Hachiya, et al.
Nature (2022) Vol. 611, Iss. 7934, pp. 115-123
Open Access | Times Cited: 344
Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies
Jingning Zhang, Diptavo Dutta, Anna Köttgen, et al.
Nature Genetics (2022) Vol. 54, Iss. 5, pp. 593-602
Open Access | Times Cited: 234
Advancing the use of genome-wide association studies for drug repurposing
William R. Reay, Murray J. Cairns
Nature Reviews Genetics (2021) Vol. 22, Iss. 10, pp. 658-671
Closed Access | Times Cited: 211
Alzheimer’s Disease: An Updated Overview of Its Genetics
Jesús Andrade-Guerrero, Alberto Santiago-Balmaseda, Paola Jeronimo-Aguilar, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3754-3754
Open Access | Times Cited: 180
Cell-type-specific cis-eQTLs in eight human brain cell types identify novel risk genes for psychiatric and neurological disorders
Julien Bryois, Daniela Calini, Will Macnair, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 8, pp. 1104-1112
Open Access | Times Cited: 179
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
Bing Bai, David Vanderwall, Yuxin Li, et al.
Molecular Neurodegeneration (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 167
Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis
Jianfeng Lin, Jiawei Zhou, Yan Xu
Brain (2023) Vol. 146, Iss. 8, pp. 3364-3372
Open Access | Times Cited: 166
Interpretable learning based Dynamic Graph Convolutional Networks for Alzheimer’s Disease analysis
Yonghua Zhu, Junbo Ma, Changan Yuan, et al.
Information Fusion (2021) Vol. 77, pp. 53-61
Closed Access | Times Cited: 137
Shared mechanisms across the major psychiatric and neurodegenerative diseases
Thomas S. Wingo, Yue Liu, Ekaterina S. Gerasimov, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 119
Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome
Jing Sun, Jianhui Zhao, Fangyuan Jiang, et al.
Genome Medicine (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 94
Identifying causal genes for depression via integration of the proteome and transcriptome from brain and blood
Yue‐Ting Deng, Ya‐Nan Ou, Bang‐Sheng Wu, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 6, pp. 2849-2857
Closed Access | Times Cited: 84
Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease
Jonggeol Jeffrey Kim, Dan Vitale, Diego Véliz Otani, et al.
Nature Genetics (2023) Vol. 56, Iss. 1, pp. 27-36
Open Access | Times Cited: 83
Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease
Wei‐Ming Su, Xiaojing Gu, Meng Dou, et al.
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 94, Iss. 11, pp. 954-961
Open Access | Times Cited: 73
Step by step: towards a better understanding of the genetic architecture of Alzheimer’s disease
Jean‐Charles Lambert, Alfredo Ramı́rez, Benjamin Grenier‐Boley, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 7, pp. 2716-2727
Open Access | Times Cited: 51
Mendelian Randomization Applied to Neurology
Éloi Gagnon, Iyas Daghlas, Loukas Zagkos, et al.
Neurology (2024) Vol. 102, Iss. 4
Open Access | Times Cited: 22
Multi-ancestry meta-analysis of tobacco use disorder identifies 461 potential risk genes and reveals associations with multiple health outcomes
Sylvanus Toikumo, Mariela Jennings, Benjamin K. Pham, et al.
Nature Human Behaviour (2024) Vol. 8, Iss. 6, pp. 1177-1193
Open Access | Times Cited: 21
Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies
Mark J. Adams, Fabian Streit, Xiangrui Meng, et al.
Cell (2025)
Open Access | Times Cited: 12
Cell state-dependent allelic effects and contextual Mendelian randomization analysis for human brain phenotypes
Alexander Haglund, Verena Zuber, Maya Abouzeid, et al.
Nature Genetics (2025)
Open Access | Times Cited: 3
Cross-ancestry genome-wide association study and systems-level integrative analyses implicate new risk genes and therapeutic targets for depression
Yifan Li, Xinglun Dang, Rui Chen, et al.
Nature Human Behaviour (2025)
Open Access | Times Cited: 3
Gene-level analysis reveals the genetic aetiology and therapeutic targets of schizophrenia
Xinglun Dang, Zhaowei Teng, Yongfeng Yang, et al.
Nature Human Behaviour (2025)
Closed Access | Times Cited: 2
Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood
Ya‐Nan Ou, Yuxiang Yang, Yue‐Ting Deng, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 10, pp. 6065-6073
Closed Access | Times Cited: 71
Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool
Carmen Romero‐Molina, Francesca Garretti, Shea J. Andrews, et al.
Neuron (2022) Vol. 110, Iss. 21, pp. 3513-3533
Open Access | Times Cited: 57
Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders
Jiewei Liu, Yuqi Cheng, Ming Li, et al.
Neuropsychopharmacology (2022) Vol. 48, Iss. 2, pp. 270-280
Open Access | Times Cited: 45
Page 1 - Next Page

Scroll to top